ES2554933T3 - Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen - Google Patents

Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen Download PDF

Info

Publication number
ES2554933T3
ES2554933T3 ES12171118.8T ES12171118T ES2554933T3 ES 2554933 T3 ES2554933 T3 ES 2554933T3 ES 12171118 T ES12171118 T ES 12171118T ES 2554933 T3 ES2554933 T3 ES 2554933T3
Authority
ES
Spain
Prior art keywords
formula
compound
cis
group
hexahydrocyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12171118.8T
Other languages
English (en)
Inventor
Nicolas Robert
Jean-Michel Lerestif
Jean-Pierre Lecouve
Marina Gaillard
Loïc Meunier
Philippe Letellier
Mathieu Boiret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Lab Serv
Les Laboratoires Servier SAS
Original Assignee
Les Lab Serv
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Lab Serv, Les Laboratoires Servier SAS filed Critical Les Lab Serv
Application granted granted Critical
Publication of ES2554933T3 publication Critical patent/ES2554933T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procedimiento de síntesis industrial del compuesto de fórmula (I):**Fórmula** caracterizado porque el compuesto de fórmula (II):**Fórmula** se somete a reacción con amoníaco a una temperatura superior a 100ºC para formar el compuesto de fórmula (III):**Fórmula** que se reduce para obtener la amina bicíclica de fórmula (IV):**Fórmula** y a continuacióneste último compuesto se somete: - bien a una reacción de acoplamiento, en condiciones básicas en un medio polar, con un compuesto de fórmula (V):**Fórmula** donde Y representa -CH2-Hal, siendo Hal un halógeno, o un grupo -CH2-OSO2-R, siendo a un grupo alquilo(C1-C6) o un grupo -C6H4-CH3, - bien a una aminación reductora en un medio ácido con un compuesto de fórmula (V'):**Fórmula** donde R' y R'' representan, independientemente entre sí, un grupo alquilo(C1-C6), o R' y R'' forman juntos un grupo -(CH2)n-, donde n >= 2-3, o uno de los grupos R' y R'' representan un átomo de hidrógeno y el otro un grupo alquilo(C1-C6), - bien a una aminación reductora con un compuesto de fórmula (V''):**Fórmula** para obtener la base libre del compuesto de fórmula (I), que se pone en presencia de ácido clorhídrico para formar el compuesto de fórmula (I), que se aísla en forma de un sólido.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
se cargan 34,74 kg de cis-octahidrociclopenta[c]pirrol en solución acuosa al 30%, 26,7 l de agua. La mezcla de reacción se lleva a reflujo hasta que se consume por completo la materia prima. Después se añade agua (13,3 l). El medio se enfría a 5ºC antes de filtrarlo y lavarlo con agua. Se obtiene el producto indicado en el título en forma de un sólido con un rendimiento del 81% y una pureza química de un 96%.
RMN1H: (600,13 MHz; dmso-d6; 300K): 7,82 (d, 2H, J = 9,0 Hz); 7,79 (bs, 1H); 7,14 (bs, 1H); 6,95 (d, 2H, J = 9,0 Hz); 4,06 (t, 2H, J = 6,5 Hz); 2,57 (m, 2H); 2,48 (m, 2H); 2,44 (bt, 2H, J = 6,5 Hz); 2,14 (bd, 2H, J = 7,5 Hz); 1,86 (qt, 2H, J = 6,5 Hz); 1,65-1,55 (m, 3H); 1,45-1,38 (m, 1H); 1,37-1,30 (m, 2H)
con bs: singlete ancho, bd: doblete ancho, bt: triplete ancho
Una caracterización del producto así formado con ayuda de las técnicas presentadas en los Ejemplos 6 a 8 demostró que se había obtenido la forma I de la base libre.
Etapa D: Clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}-benzamida
En un reactor se introducen 14,69 kg de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida y 122 l de agua. Además, se prepara una solución de 6,81 kg de ácido chlorhídrico al 37% en 11,54 l de agua. Luego se añaden al reactor 13,75 kg de esta solución ácida. La mezcla se agita durante 1 hora a temperatura ambiente y después 1h30 a 60ºC. La suspensión se filtra en caliente y después el filtro se enjuaga con agua. A continuación, se efectúa en el filtrado un cambio de disolvente con volumen constante para obtener una relación isopropanol/agua de 9/1. El producto se aísla a 0ºC y el precipitado obtenido se lava con isopropanol. Finalmente se obtiene el producto indicado en el título con un rendimiento de un 89% y una pureza química superior al 99%.
Una caracterización del producto así formado con ayuda de las técnicas presentadas en los Ejemplos 4 a 5 demostró que se había obtenido la forma I del clorhidrato.
Etapa E: Clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi-benzamida
La sal de clorhidrato obtenida en la Etapa D se recristaliza en una mezcla de isopropanol (264 kg) y agua (37,4 l). La mezcla se lleva a reflujo durante 45 minutos. La solución se filtra en caliente y después se enjuaga mediante isopropanol. A continuación, se inicia la cristalización a 55ºC. El medio se mantiene a esta temperatura durante 40 minutos antes de enfriarlo a 0ºC. Al cabo de unas horas, el producto se aísla por filtración. Después de lavado con isopropanol se obtiene el producto indicado en el título en forma de un polvo, con un rendimiento de un 93% y una pureza química superior al 99%.Punto de fusión: 213-215ºC
Una caracterización del producto así formado con ayuda de las técnicas presentadas en los Ejemplos 4 a 5 demostró que se había obtenido la forma I del clorhidrato.
Ejemplo 2: Clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida
Etapa A: Tetrahidrociclopenta[c]pirrol-1,3(2H,3aH)-diona
El protocolo es idéntico al descrito en la Etapa A del Ejemplo 1.
Etapa B: cis-octahidrociclopenta[c]pirrol
El protocolo es idéntico al descrito en la Etapa B del Ejemplo 1.
Etapa C: 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida
En un reactor se introducen 15,2 kg de 4-(3-cloropropoxi)benzamida, 40,28 kg de cisoctahidrociclopenta[c]pirrol en solución acuosa al 30%, 63,84 kg de agua, 21,48 kg de isopropanol y 14,39 kg de trietilamina. La mezcla de reacción se agita y se calienta a reflujo hasta que se consume por completo la
-9
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES12171118.8T 2011-06-08 2012-06-07 Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen Active ES2554933T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1101746 2011-06-08
FR1101746A FR2976285B1 (fr) 2011-06-08 2011-06-08 Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
ES2554933T3 true ES2554933T3 (es) 2015-12-28

Family

ID=46172744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12171118.8T Active ES2554933T3 (es) 2011-06-08 2012-06-07 Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen

Country Status (45)

Country Link
US (3) US8664408B2 (es)
EP (1) EP2532651B1 (es)
JP (2) JP5680022B2 (es)
KR (2) KR20120136296A (es)
CN (1) CN102816102A (es)
AP (1) AP2012006280A0 (es)
AR (1) AR086848A1 (es)
AU (1) AU2012203062B2 (es)
BR (1) BR102012013573A2 (es)
CA (1) CA2779045C (es)
CL (1) CL2012001500A1 (es)
CO (1) CO6580197A1 (es)
CR (1) CR20120274A (es)
CU (1) CU20120087A7 (es)
CY (1) CY1116739T1 (es)
DK (1) DK2532651T3 (es)
EA (1) EA022741B1 (es)
EC (1) ECSP12011941A (es)
ES (1) ES2554933T3 (es)
FR (1) FR2976285B1 (es)
GE (1) GEP20156395B (es)
GT (1) GT201200182A (es)
HR (1) HRP20151073T1 (es)
HU (1) HUE028050T2 (es)
IL (1) IL219925A0 (es)
MA (1) MA33883B1 (es)
MD (1) MD4345C1 (es)
ME (1) ME02346B (es)
MX (1) MX2012006525A (es)
NI (1) NI201200102A (es)
PE (1) PE20130046A1 (es)
PH (1) PH12012000124A1 (es)
PL (1) PL2532651T3 (es)
PT (1) PT2532651E (es)
PY (1) PY1226950A (es)
RS (1) RS54279B1 (es)
RU (1) RU2013158817A (es)
SG (1) SG186546A1 (es)
SI (1) SI2532651T1 (es)
SV (1) SV2012004237A (es)
TN (1) TN2012000254A1 (es)
TW (1) TWI499584B (es)
UY (1) UY34110A (es)
WO (1) WO2012168657A1 (es)
ZA (1) ZA201204183B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
CN103601666B (zh) * 2013-11-28 2015-09-02 遵义医学院 八氢环戊烷[c]吡咯的制备方法
CN104387313B (zh) * 2014-10-22 2015-12-30 滨海博大化工有限公司 一种1,2-环戊二甲酰亚胺的制备方法
KR101966221B1 (ko) * 2017-06-14 2019-04-12 최상근 유해가스 처리 장치
CN115232058A (zh) * 2022-08-01 2022-10-25 上海巽田科技股份有限公司 一种格列齐特中间体1,2-环戊二甲酰胺的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US756120A (en) * 1902-07-28 1904-03-29 Krupp Gmbh Recoil-gun with special devices for protecting the slide-tracks from dust.
NL132376C (es) * 1966-02-10
US4895840A (en) * 1987-06-10 1990-01-23 A. H. Robins Company, Incorporated N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or n'n')alkylaminoalkyl ureas and cyanoguanidines
CN1314340A (zh) * 2000-03-21 2001-09-26 山东省医药工业研究所 环戊烷酰亚胺的制备方法
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN100424077C (zh) * 2005-06-07 2008-10-08 台州市四维化工厂 一种环戊烷1，2-二酰亚胺的制备方法
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
AR074226A1 (es) * 2008-11-26 2010-12-29 Abbott Lab Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor.
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CA2779045C (fr) 2016-06-21
UY34110A (es) 2013-01-03
JP2012254982A (ja) 2012-12-27
AU2012203062A1 (en) 2013-01-10
DK2532651T3 (en) 2015-11-09
CL2012001500A1 (es) 2014-09-05
AP2012006280A0 (en) 2012-06-30
EP2532651B1 (fr) 2015-08-05
WO2012168657A1 (fr) 2012-12-13
AR086848A1 (es) 2014-01-29
CO6580197A1 (es) 2012-12-17
MA33883B1 (fr) 2013-01-02
TWI499584B (zh) 2015-09-11
US8664408B2 (en) 2014-03-04
US20140100374A1 (en) 2014-04-10
CA2779045A1 (fr) 2012-12-08
IL219925A0 (en) 2012-10-31
EA201200726A1 (ru) 2013-04-30
PY1226950A (es) 2015-05-01
RU2013158817A (ru) 2015-07-20
HRP20151073T1 (hr) 2015-11-06
MD20120049A2 (ro) 2012-12-31
EA022741B1 (ru) 2016-02-29
US20140155453A1 (en) 2014-06-05
SI2532651T1 (sl) 2015-10-30
TN2012000254A1 (fr) 2013-12-12
PE20130046A1 (es) 2013-02-10
KR20120136296A (ko) 2012-12-18
ME02346B (me) 2016-06-20
GEP20156395B (en) 2015-11-10
PL2532651T3 (pl) 2016-01-29
PT2532651E (pt) 2015-10-15
TW201302702A (zh) 2013-01-16
EP2532651A1 (fr) 2012-12-12
KR20140079346A (ko) 2014-06-26
BR102012013573A2 (pt) 2013-07-02
SV2012004237A (es) 2013-01-04
GT201200182A (es) 2014-09-18
HUE028050T2 (en) 2016-11-28
FR2976285B1 (fr) 2013-05-24
JP2015044840A (ja) 2015-03-12
MD4345B1 (ro) 2015-04-30
PH12012000124A1 (en) 2014-01-20
CR20120274A (es) 2013-01-11
CU20120087A7 (es) 2014-01-29
MX2012006525A (es) 2013-01-09
MD4345C1 (ro) 2015-11-30
CY1116739T1 (el) 2017-03-15
RS54279B1 (sr) 2016-02-29
NZ600474A (en) 2013-12-20
US20120316214A1 (en) 2012-12-13
AU2012203062B2 (en) 2015-05-07
ZA201204183B (en) 2013-02-27
JP5680022B2 (ja) 2015-03-04
NI201200102A (es) 2012-08-20
US8952179B2 (en) 2015-02-10
ECSP12011941A (es) 2012-07-31
CN102816102A (zh) 2012-12-12
FR2976285A1 (fr) 2012-12-14
SG186546A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
AU2015341788B2 (en) Synthesis of copanlisib and its dihydrochloride salt
JP2020114842A (ja) ジアリールチオヒダントイン化合物を調製するためのプロセス
EA013820B1 (ru) Дигидроптеридиноны, способ их получения, промежуточные соединения
MXPA04006992A (es) Procedimiento para preparar derivados de indolinona.
KR20170039121A (ko) 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
KR20170036677A (ko) 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
CZ2008669A3 (cs) Zpusob prípravy dabigatranu a jeho meziprodukty
JP2020528916A (ja) タンパク質キナーゼに対する選択的阻害剤の合成に有用な中間体及びそれを調製するためのプロセス
TW201315725A (zh) 藉由苯并□酮與胺反應製備經四唑取代之鄰胺苯甲酸二醯胺衍生物的方法
KR20120046248A (ko) 2-아미노-5-트리플루오로메틸피리미딘 유도체의 위치선택적 제조
JP2013531004A (ja) トロンビン特異的インヒビターの調製のための中間体及び方法
JP2013537875A5 (es)
DK2532651T3 (en) Synthesis process and the crystal form of 4- {3- [cis-hexahydrocyclopenta [c] pyrrole-2 (1 H) -yl] propoxy} benzamide hydrochloride and the free base thereof, and the pharmaceutical compositions containing them
BRPI0711384A2 (pt) derivados bicìclicos como inibidores de cetp
US20120046463A1 (en) Process for the Preparation of Imatinib Base
US8748615B2 (en) Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
CZ2013943A3 (cs) Krystalické formy vemurafenibu
MX2015000056A (es) Derivados de imidazo[2,1b]tiazol, su preparación y su uso como medicamentos.
ES2664782T3 (es) Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
Rahimizadeh et al. Vicarious nucleophilic substitution in nitro derivatives of imidazo [1, 2-a] pyridine
KR101752449B1 (ko) 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법
CN103339124A (zh) 二(芳氨基)芳基化合物的制备方法及其合成中间体
JP2014118357A (ja) 置換ピラゾロピリミジン化合物、及びその合成中間体の製法
KR101152607B1 (ko) ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
CA2627590A1 (en) Method for the production of quinazolinone derivatives